In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lab Relief

Executive Summary

Reference laboratories, which have suffered for most of the past decade from ever-declining reimbursement rates, had a welcome piece of good news this year--as of Jan. 1, Medicare reimbursement for many anatomic pathology processes is slated to increase. The increases vary by procedure, but some of the biggest categories--biopsies, for example--will rise by as much as 33% over the next three years. Reimbursement for Pap smears is doubling, although Medicare is responsible for only a small portion of pap smears. The reimbursement hike caused Dianon to restate its revenue projections for this fiscal year from a 30% increase to a 40% increase.

You may also be interested in...



Impath's Informatics Play

Impath's unorthodox step into the cancer information business has made it attractive to Wall Street, but will its vast, specialized databases allow it to reap benefits from pharmacogenetics? The real value to Impath of its databases resides in their ability to promote work on targeted therapeutics, whose use in patients will depend on critical markers. But targeted therapeutics are a controversial concept that requires pharma companies to make basic changes in the way they operate. There's no guarantee Impath can get the pay-off it wants from its new initiatives.

ASCO 2023 – Roche Sees Morpheus And Takes The Red Pill

The company’s TIGIT data are strong enough for a phase 3 trial to be launched, ASCO learns.

ASCO 2023 – Bicara Eyes Head And Neck Niche

Impressive data in HPV-negative disease, potentially beating Keytruda, has the private group making pivotal plans.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV001390

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel